Previous studies revealed that CTLA-4 expression was detected via immunohistochemistry in tumor-infiltrating lymphocytes, and higher staining scores or frequencies of positive cells were associated with poor clinical outcomes in canine mammary gland and melanocytic tumors (32, 33). The gene discussed is CTLA4; the disease is neoplasm.